TVTX•benzinga•
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $45
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 12, 2025 by benzinga